Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465793 | 0.87 | MAPT (0.47) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL4004428 | 0.87 | MAPT (0.47) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL5150276 | 0.83 | MAPT (0.44) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL4459077 | 0.82 | MAPT (0.45) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL13671236 | 0.81 | MAPT (0.46) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL5154507 | 0.81 | MEN1 (0.42) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL13671244 | 0.80 | MAPT (0.49) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL19212420 | 0.80 | GPR119 (0.54) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL29707387 | 0.80 | GPR119 (0.54) | GPR119MAPTKDM4ETHRBMEN1 | |
| SCHEMBL19702760 | 0.80 | MAPT (0.53) | GPR119MAPTKDM4ETHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | GPR119 17/4885MAPT 2788/4885KDM4E 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.